BeyondSpring Inc. (BYSI) 10-Year Financial Performance & Capital Metrics

BYSI • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutBeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.Show more

Revenue $0
EBITDA -$8M +42.7%
Net Income -$11M +47.1%
EPS (Diluted) -0.28 +48.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 14 (bottom 14%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM95.59%

EPS CAGR

10Y-

5Y-

3Y-

TTM110.1%

ROCE

10Y Avg-206.08%

5Y Avg-67.93%

3Y Avg-56.14%

Latest-43.6%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	180K	1.35M	1.35M	0	0
Revenue Growth %	-	-	-	-	-	-	6.51%	0%	-1%	-
Cost of Goods Sold+	10K	18K	32K	48K	77K	0	0	0	302K	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-10K	-18K	-32K	-48K	-77K	180K	1.35M	1.35M	-302K	0
Gross Margin %	-	-	-	-	-	1%	1%	1%	-	-
Gross Profit Growth %	-	-0.8%	-0.78%	-0.5%	-0.6%	3.34%	6.51%	0%	-1.22%	1%
Operating Expenses+	7.47M	12.37M	97.98M	57.55M	40.23M	64.39M	67.59M	38.59M	14.78M	8.75M
OpEx % of Revenue	-	-	-	-	-	357.73%	50.03%	28.56%	-	-
Selling, General & Admin	1.19M	1.93M	9.05M	5.93M	8.89M	22.6M	30.7M	13.01M	7.51M	6.11M
SG&A % of Revenue	-	-	-	-	-	125.54%	22.73%	9.63%	-	-
Research & Development	6.28M	10.44M	88.93M	51.62M	31.34M	41.79M	36.89M	25.58M	7.27M	2.64M
R&D % of Revenue	-	-	-	-	-	232.18%	27.3%	18.94%	-	-
Other Operating Expenses	0	0	918K	315K	0	0	0	0	0	0
Operating Income+	-7.47M	-12.37M	-97.98M	-57.55M	-40.31M	-64.21M	-66.24M	-37.24M	-15.08M	-8.75M
Operating Margin %	-	-	-	-	-	-356.73%	-49.03%	-27.56%	-	-
Operating Income Growth %	-2.54%	-0.65%	-6.92%	0.41%	0.3%	-0.59%	-0.03%	0.44%	0.6%	0.42%
EBITDA+	-7.46M	-12.35M	-97.95M	-57.5M	-40.23M	-64.13M	-66.18M	-36.09M	-14.78M	-8.47M
EBITDA Margin %	-	-	-	-	-	-356.3%	-48.99%	-26.72%	-	-
EBITDA Growth %	-2.41%	-0.65%	-6.93%	0.41%	0.3%	-0.59%	-0.03%	0.45%	0.59%	0.43%
D&A (Non-Cash Add-back)	10K	18K	32K	48K	77K	77K	61K	1.14M	302K	285K
EBIT	-7.48M	-12.37M	-96.39M	-57.47M	-40.13M	-63.74M	-64.55M	-36.1M	-13.92M	-8.75M
Net Interest Income+	-519K	-159K	120K	211K	-22K	31K	11K	178K	421K	59K
Interest Income	13K	18K	120K	211K	184K	116K	98K	195K	421K	59K
Interest Expense	532K	177K	0	0	206K	85K	87K	17K	0	0
Other Income/Expense	-577K	-177K	1.59M	71K	-26K	390K	1.6M	1.12M	1.16M	-15K
Pretax Income+	-8.05M	-12.54M	-96.39M	-57.47M	-40.33M	-63.82M	-64.64M	-36.12M	-13.92M	-8.77M
Pretax Margin %	-	-	-	-	-	-354.56%	-47.84%	-26.73%	-	-
Income Tax+	495K	0	0	0	0	0	3.57M	163K	92K	96K
Effective Tax Rate %	0.99%	0.96%	0.95%	0.95%	0.94%	0.96%	0.99%	0.92%	1.51%	1.27%
Net Income+	-7.97M	-12.01M	-91.76M	-54.87M	-38.09M	-60.97M	-64.18M	-33.28M	-21.03M	-11.12M
Net Margin %	-	-	-	-	-	-338.74%	-47.5%	-24.63%	-	-
Net Income Growth %	-1.65%	-0.51%	-6.64%	0.4%	0.31%	-0.6%	-0.05%	0.48%	0.37%	0.47%
Net Income (Continuing)	-8.01M	-12.54M	-96.39M	-57.47M	-40.33M	-63.82M	-68.21M	-36.28M	-14.02M	-8.87M
Discontinued Operations	0	0	0	0	0	0	0	0	-7.93M	-2.65M
Minority Interest	708K	147K	960K	-1.62M	854K	3.48M	-5.76M	2.97M	3.34M	18.61M
EPS (Diluted)+	-0.50	-0.71	-4.40	-2.42	-1.55	-2.04	-1.64	-0.85	-0.54	-0.28
EPS Growth %	-1.63%	-0.42%	-5.2%	0.45%	0.36%	-0.32%	0.2%	0.48%	0.36%	0.48%
EPS (Basic)	-0.53	-0.75	-4.40	-2.42	-1.55	-2.04	-1.64	-0.85	-0.54	-0.28
Diluted Shares Outstanding	15.82M	16.88M	20.87M	22.67M	24.65M	29.98M	39.02M	39.09M	39M	39.73M
Basic Shares Outstanding	15.17M	16.09M	20.87M	22.67M	24.65M	29.98M	39.02M	39.09M	39M	39.73M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	10.94M	14.71M	32.34M	5.87M	40.86M	113.4M	75.12M	38.52M	18.42M	28.58M
Cash & Short-Term Investments	10.82M	11.69M	30.55M	3.89M	35.93M	109.54M	72.37M	37.27M	15.34M	2.92M
Cash Only	10.82M	11.69M	27.48M	3.89M	35.93M	109.54M	41.63M	34.4M	15.34M	2.92M
Short-Term Investments	0	0	3.07M	0	0	0	30.74M	2.87M	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	89K	799K	0	1.21M	0	0	0	0	0	0
Days Inventory Outstanding	3.25K	16.2K	-	9.19K	-	-	-	-	-	-
Other Current Assets	26K	2.66M	264K	1.69M	410K	358K	1.02M	763K	2.79M	25.41M
Total Non-Current Assets+	34K	201K	484K	1.19M	3.69M	3.64M	6.53M	7.7M	6.39M	5.74M
Property, Plant & Equipment	34K	80K	123K	282K	2.75M	2.36M	4.95M	7.35M	1.05M	752K
Fixed Asset Turnover	-	-	-	-	-	0.08x	0.27x	0.18x	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	121K	361K	910K	946K	1.28M	1.57M	347K	5.34M	4.99M
Total Assets+	10.97M	14.91M	32.83M	7.06M	44.55M	117.04M	81.65M	46.22M	24.81M	34.31M
Asset Turnover	-	-	-	-	-	0.00x	0.02x	0.03x	-	-
Asset Growth %	8.34%	0.36%	1.2%	-0.78%	5.31%	1.63%	-0.3%	-0.43%	-0.46%	0.38%
Total Current Liabilities+	1.31M	2.61M	4.79M	16.45M	10.05M	13.77M	15.15M	7.35M	7.96M	11.01M
Accounts Payable	300K	444K	3.38M	9.59M	2.54M	2.22M	1.66M	1.08M	561K	295K
Days Payables Outstanding	10.95K	9K	38.54K	72.89K	12.03K	-	-	-	678.03	-
Short-Term Debt	0	210K	0	0	29K	0	1.57M	0	258K	0
Deferred Revenue (Current)	0	1000K	0	0	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	802K	523K	606K	1.36M	-6.02M	2.95M	6.17M	1.45M	4.4M	-17.58M
Current Ratio	8.34x	5.64x	6.75x	0.36x	4.06x	8.24x	4.96x	5.24x	2.31x	2.60x
Quick Ratio	8.27x	5.33x	6.75x	0.28x	4.06x	8.24x	4.96x	5.24x	2.31x	2.60x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	300K	654K	3.38M	9.59M	3.37M	11.45M	45.57M	41.88M	40.31M	37.59M
Long-Term Debt	0	0	0	0	1.44M	2.17M	0	0	0	0
Capital Lease Obligations	0	0	0	0	1.94M	1.36M	1.47M	4M	589K	307K
Deferred Tax Liabilities	0	0	0	0	0	0	5.45M	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	709K	3.66M	11.55M	9.88M
Total Liabilities	1.31M	2.61M	4.79M	16.45M	13.42M	25.22M	60.73M	49.23M	48.27M	48.6M
Total Debt+	0	210K	0	0	3.94M	4.31M	3.58M	4.96M	847K	589K
Net Debt	-10.82M	-11.48M	-27.48M	-3.89M	-32M	-105.22M	-38.05M	-29.43M	-14.49M	-2.33M
Debt / Equity	-	0.02x	-	-	0.13x	0.05x	0.17x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-14.05x	-69.88x	-	-	-195.67x	-755.42x	-761.38x	-2190.53x	-	-
Total Equity+	9.66M	12.3M	28.04M	-9.38M	31.13M	91.82M	20.92M	-3.01M	-23.46M	-14.29M
Equity Growth %	2.03%	0.27%	1.28%	-1.33%	4.32%	1.95%	-0.77%	-1.14%	-6.8%	0.39%
Book Value per Share	0.61	0.73	1.34	-0.41	1.26	3.06	0.54	-0.08	-0.60	-0.36
Total Shareholders' Equity	8.95M	12.15M	27.08M	-7.77M	30.28M	88.34M	26.68M	-5.98M	-26.8M	-32.9M
Common Stock	2K	2K	2K	2K	3K	4K	4K	4K	4K	4K
Retained Earnings	-20.12M	-32.13M	-123.89M	-178.76M	-216.84M	-277.82M	-342M	-375.28M	-396.3M	-407.43M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-53K	-91K	-182K	42K	140K	-297K	-523K	436K	894K	1.34M
Minority Interest	708K	147K	960K	-1.62M	854K	3.48M	-5.76M	2.97M	3.34M	18.61M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-6.57M	-13.7M	-28.8M	-39.95M	-48.16M	-43.74M	-47.24M	-28.15M	-16.47M	-16.44M
Operating CF Margin %	-	-	-	-	-	-243.03%	-34.97%	-20.84%	-	-
Operating CF Growth %	-4.73%	-1.08%	-1.1%	-0.39%	-0.21%	0.09%	-0.08%	0.4%	0.41%	0%
Net Income	-8.05M	-12.54M	-96.39M	-57.47M	-38.09M	-63.82M	-68.21M	-36.28M	-21.03M	-11.12M
Depreciation & Amortization	10K	18K	32K	48K	77K	77K	61K	232K	302K	285K
Stock-Based Compensation	0	0	22.68M	6.56M	0	8.19M	3.15M	1.67M	554K	2.06M
Deferred Taxes	0	0	0	0	0	0	-1.2M	0	0	0
Other Non-Cash Items	1.42M	67K	42.26M	-307K	-147K	659K	546K	-178K	988K	-6.29M
Working Capital Changes	55K	-1.17M	2.62M	11.22M	-10.01M	11.15M	18.41M	6.41M	2.71M	-1.38M
Change in Receivables	0	0	0	0	481K	0	-1.77M	0	0	0
Change in Inventory	-73K	-710K	-726K	316K	-3.31M	0	1.77M	0	186K	-19K
Change in Payables	94K	144K	2.94M	6.21M	-7.05M	-321K	-560K	-575K	0	0
Cash from Investing+	355K	-64K	-3.15M	2.87M	10.08M	-52K	-20.41M	18.25M	-100K	-12.01M
Capital Expenditures	-40K	-64K	-76K	-207K	-4K	-52K	-2.84M	-34K	-100K	-224K
CapEx % of Revenue	-	-	-	-	-	0.29%	2.11%	0.03%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-861K	-64K	-3.07M	3.07M	0	0	-20.41M	717K	0	-11.79M
Cash from Financing+	16.67M	14.71M	47.72M	13.24M	70.09M	117.83M	1K	3.43M	4K	26.79M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-1.2M	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	-537K	-2.78M	-755K	0	4.65M	-38K	5M	4K	22.87M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-6.61M	-13.76M	-28.87M	-40.16M	-48.17M	-43.8M	-50.09M	-28.18M	-16.57M	-16.67M
FCF Margin %	-	-	-	-	-	-243.32%	-37.07%	-20.86%	-	-
FCF Growth %	-4.77%	-1.08%	-1.1%	-0.39%	-0.2%	0.09%	-0.14%	0.44%	0.41%	-0.01%
FCF per Share	-0.42	-0.82	-1.38	-1.77	-1.95	-1.46	-1.28	-0.72	-0.43	-0.42
FCF Conversion (FCF/Net Income)	0.82x	1.14x	0.31x	0.73x	1.26x	0.72x	0.74x	0.85x	0.78x	1.48x
Interest Paid	0	0	0	0	0	85K	91K	17K	0	0
Taxes Paid	0	0	0	0	0	0	22K	367K	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-6015.09%	-109.4%	-455%	-588.28%	-350.22%	-99.18%	-113.85%	-371.5%	-	-
Return on Invested Capital (ROIC)	-	-	-10673.31%	-	-	-	-	-	-	-
Gross Margin	-	-	-	-	-	100%	100%	100%	-	-
Net Margin	-	-	-	-	-	-33873.89%	-4750.48%	-2463.29%	-	-
Debt / Equity	-	0.02x	-	-	0.13x	0.05x	0.17x	-	-	-
Interest Coverage	-14.05x	-69.88x	-	-	-195.67x	-755.42x	-761.38x	-2190.53x	-	-
FCF Conversion	0.82x	1.14x	0.31x	0.73x	1.26x	0.72x	0.74x	0.85x	0.78x	1.48x
Revenue Growth	-	-	-	-	-	-	650.56%	0%	-100%	-

Frequently Asked Questions

Growth & Financials

BeyondSpring Inc. (BYSI) grew revenue by 0.0% over the past year. Growth has been modest.

BeyondSpring Inc. (BYSI) reported a net loss of $0.6M for fiscal year 2024.

Dividend & Returns

BeyondSpring Inc. (BYSI) had negative free cash flow of $14.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

BeyondSpring Inc. (BYSI) 10-Year Financial Performance & Capital Metrics

BYSI • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $0
EBITDA -$8M +42.7%
Net Income -$11M +47.1%
EPS (Diluted) -0.28 +48.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 14 (bottom 14%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM95.59%

EPS CAGR

10Y-

5Y-

3Y-

TTM110.1%

ROCE

10Y Avg-206.08%

5Y Avg-67.93%

3Y Avg-56.14%

Latest-43.6%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	180K	1.35M	1.35M	0	0
Revenue Growth %	-	-	-	-	-	-	6.51%	0%	-1%	-
Cost of Goods Sold+	10K	18K	32K	48K	77K	0	0	0	302K	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-10K	-18K	-32K	-48K	-77K	180K	1.35M	1.35M	-302K	0
Gross Margin %	-	-	-	-	-	1%	1%	1%	-	-
Gross Profit Growth %	-	-0.8%	-0.78%	-0.5%	-0.6%	3.34%	6.51%	0%	-1.22%	1%
Operating Expenses+	7.47M	12.37M	97.98M	57.55M	40.23M	64.39M	67.59M	38.59M	14.78M	8.75M
OpEx % of Revenue	-	-	-	-	-	357.73%	50.03%	28.56%	-	-
Selling, General & Admin	1.19M	1.93M	9.05M	5.93M	8.89M	22.6M	30.7M	13.01M	7.51M	6.11M
SG&A % of Revenue	-	-	-	-	-	125.54%	22.73%	9.63%	-	-
Research & Development	6.28M	10.44M	88.93M	51.62M	31.34M	41.79M	36.89M	25.58M	7.27M	2.64M
R&D % of Revenue	-	-	-	-	-	232.18%	27.3%	18.94%	-	-
Other Operating Expenses	0	0	918K	315K	0	0	0	0	0	0
Operating Income+	-7.47M	-12.37M	-97.98M	-57.55M	-40.31M	-64.21M	-66.24M	-37.24M	-15.08M	-8.75M
Operating Margin %	-	-	-	-	-	-356.73%	-49.03%	-27.56%	-	-
Operating Income Growth %	-2.54%	-0.65%	-6.92%	0.41%	0.3%	-0.59%	-0.03%	0.44%	0.6%	0.42%
EBITDA+	-7.46M	-12.35M	-97.95M	-57.5M	-40.23M	-64.13M	-66.18M	-36.09M	-14.78M	-8.47M
EBITDA Margin %	-	-	-	-	-	-356.3%	-48.99%	-26.72%	-	-
EBITDA Growth %	-2.41%	-0.65%	-6.93%	0.41%	0.3%	-0.59%	-0.03%	0.45%	0.59%	0.43%
D&A (Non-Cash Add-back)	10K	18K	32K	48K	77K	77K	61K	1.14M	302K	285K
EBIT	-7.48M	-12.37M	-96.39M	-57.47M	-40.13M	-63.74M	-64.55M	-36.1M	-13.92M	-8.75M
Net Interest Income+	-519K	-159K	120K	211K	-22K	31K	11K	178K	421K	59K
Interest Income	13K	18K	120K	211K	184K	116K	98K	195K	421K	59K
Interest Expense	532K	177K	0	0	206K	85K	87K	17K	0	0
Other Income/Expense	-577K	-177K	1.59M	71K	-26K	390K	1.6M	1.12M	1.16M	-15K
Pretax Income+	-8.05M	-12.54M	-96.39M	-57.47M	-40.33M	-63.82M	-64.64M	-36.12M	-13.92M	-8.77M
Pretax Margin %	-	-	-	-	-	-354.56%	-47.84%	-26.73%	-	-
Income Tax+	495K	0	0	0	0	0	3.57M	163K	92K	96K
Effective Tax Rate %	0.99%	0.96%	0.95%	0.95%	0.94%	0.96%	0.99%	0.92%	1.51%	1.27%
Net Income+	-7.97M	-12.01M	-91.76M	-54.87M	-38.09M	-60.97M	-64.18M	-33.28M	-21.03M	-11.12M
Net Margin %	-	-	-	-	-	-338.74%	-47.5%	-24.63%	-	-
Net Income Growth %	-1.65%	-0.51%	-6.64%	0.4%	0.31%	-0.6%	-0.05%	0.48%	0.37%	0.47%
Net Income (Continuing)	-8.01M	-12.54M	-96.39M	-57.47M	-40.33M	-63.82M	-68.21M	-36.28M	-14.02M	-8.87M
Discontinued Operations	0	0	0	0	0	0	0	0	-7.93M	-2.65M
Minority Interest	708K	147K	960K	-1.62M	854K	3.48M	-5.76M	2.97M	3.34M	18.61M
EPS (Diluted)+	-0.50	-0.71	-4.40	-2.42	-1.55	-2.04	-1.64	-0.85	-0.54	-0.28
EPS Growth %	-1.63%	-0.42%	-5.2%	0.45%	0.36%	-0.32%	0.2%	0.48%	0.36%	0.48%
EPS (Basic)	-0.53	-0.75	-4.40	-2.42	-1.55	-2.04	-1.64	-0.85	-0.54	-0.28
Diluted Shares Outstanding	15.82M	16.88M	20.87M	22.67M	24.65M	29.98M	39.02M	39.09M	39M	39.73M
Basic Shares Outstanding	15.17M	16.09M	20.87M	22.67M	24.65M	29.98M	39.02M	39.09M	39M	39.73M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	10.94M	14.71M	32.34M	5.87M	40.86M	113.4M	75.12M	38.52M	18.42M	28.58M
Cash & Short-Term Investments	10.82M	11.69M	30.55M	3.89M	35.93M	109.54M	72.37M	37.27M	15.34M	2.92M
Cash Only	10.82M	11.69M	27.48M	3.89M	35.93M	109.54M	41.63M	34.4M	15.34M	2.92M
Short-Term Investments	0	0	3.07M	0	0	0	30.74M	2.87M	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	89K	799K	0	1.21M	0	0	0	0	0	0
Days Inventory Outstanding	3.25K	16.2K	-	9.19K	-	-	-	-	-	-
Other Current Assets	26K	2.66M	264K	1.69M	410K	358K	1.02M	763K	2.79M	25.41M
Total Non-Current Assets+	34K	201K	484K	1.19M	3.69M	3.64M	6.53M	7.7M	6.39M	5.74M
Property, Plant & Equipment	34K	80K	123K	282K	2.75M	2.36M	4.95M	7.35M	1.05M	752K
Fixed Asset Turnover	-	-	-	-	-	0.08x	0.27x	0.18x	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	121K	361K	910K	946K	1.28M	1.57M	347K	5.34M	4.99M
Total Assets+	10.97M	14.91M	32.83M	7.06M	44.55M	117.04M	81.65M	46.22M	24.81M	34.31M
Asset Turnover	-	-	-	-	-	0.00x	0.02x	0.03x	-	-
Asset Growth %	8.34%	0.36%	1.2%	-0.78%	5.31%	1.63%	-0.3%	-0.43%	-0.46%	0.38%
Total Current Liabilities+	1.31M	2.61M	4.79M	16.45M	10.05M	13.77M	15.15M	7.35M	7.96M	11.01M
Accounts Payable	300K	444K	3.38M	9.59M	2.54M	2.22M	1.66M	1.08M	561K	295K
Days Payables Outstanding	10.95K	9K	38.54K	72.89K	12.03K	-	-	-	678.03	-
Short-Term Debt	0	210K	0	0	29K	0	1.57M	0	258K	0
Deferred Revenue (Current)	0	1000K	0	0	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	802K	523K	606K	1.36M	-6.02M	2.95M	6.17M	1.45M	4.4M	-17.58M
Current Ratio	8.34x	5.64x	6.75x	0.36x	4.06x	8.24x	4.96x	5.24x	2.31x	2.60x
Quick Ratio	8.27x	5.33x	6.75x	0.28x	4.06x	8.24x	4.96x	5.24x	2.31x	2.60x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	300K	654K	3.38M	9.59M	3.37M	11.45M	45.57M	41.88M	40.31M	37.59M
Long-Term Debt	0	0	0	0	1.44M	2.17M	0	0	0	0
Capital Lease Obligations	0	0	0	0	1.94M	1.36M	1.47M	4M	589K	307K
Deferred Tax Liabilities	0	0	0	0	0	0	5.45M	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	709K	3.66M	11.55M	9.88M
Total Liabilities	1.31M	2.61M	4.79M	16.45M	13.42M	25.22M	60.73M	49.23M	48.27M	48.6M
Total Debt+	0	210K	0	0	3.94M	4.31M	3.58M	4.96M	847K	589K
Net Debt	-10.82M	-11.48M	-27.48M	-3.89M	-32M	-105.22M	-38.05M	-29.43M	-14.49M	-2.33M
Debt / Equity	-	0.02x	-	-	0.13x	0.05x	0.17x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-14.05x	-69.88x	-	-	-195.67x	-755.42x	-761.38x	-2190.53x	-	-
Total Equity+	9.66M	12.3M	28.04M	-9.38M	31.13M	91.82M	20.92M	-3.01M	-23.46M	-14.29M
Equity Growth %	2.03%	0.27%	1.28%	-1.33%	4.32%	1.95%	-0.77%	-1.14%	-6.8%	0.39%
Book Value per Share	0.61	0.73	1.34	-0.41	1.26	3.06	0.54	-0.08	-0.60	-0.36
Total Shareholders' Equity	8.95M	12.15M	27.08M	-7.77M	30.28M	88.34M	26.68M	-5.98M	-26.8M	-32.9M
Common Stock	2K	2K	2K	2K	3K	4K	4K	4K	4K	4K
Retained Earnings	-20.12M	-32.13M	-123.89M	-178.76M	-216.84M	-277.82M	-342M	-375.28M	-396.3M	-407.43M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-53K	-91K	-182K	42K	140K	-297K	-523K	436K	894K	1.34M
Minority Interest	708K	147K	960K	-1.62M	854K	3.48M	-5.76M	2.97M	3.34M	18.61M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-6.57M	-13.7M	-28.8M	-39.95M	-48.16M	-43.74M	-47.24M	-28.15M	-16.47M	-16.44M
Operating CF Margin %	-	-	-	-	-	-243.03%	-34.97%	-20.84%	-	-
Operating CF Growth %	-4.73%	-1.08%	-1.1%	-0.39%	-0.21%	0.09%	-0.08%	0.4%	0.41%	0%
Net Income	-8.05M	-12.54M	-96.39M	-57.47M	-38.09M	-63.82M	-68.21M	-36.28M	-21.03M	-11.12M
Depreciation & Amortization	10K	18K	32K	48K	77K	77K	61K	232K	302K	285K
Stock-Based Compensation	0	0	22.68M	6.56M	0	8.19M	3.15M	1.67M	554K	2.06M
Deferred Taxes	0	0	0	0	0	0	-1.2M	0	0	0
Other Non-Cash Items	1.42M	67K	42.26M	-307K	-147K	659K	546K	-178K	988K	-6.29M
Working Capital Changes	55K	-1.17M	2.62M	11.22M	-10.01M	11.15M	18.41M	6.41M	2.71M	-1.38M
Change in Receivables	0	0	0	0	481K	0	-1.77M	0	0	0
Change in Inventory	-73K	-710K	-726K	316K	-3.31M	0	1.77M	0	186K	-19K
Change in Payables	94K	144K	2.94M	6.21M	-7.05M	-321K	-560K	-575K	0	0
Cash from Investing+	355K	-64K	-3.15M	2.87M	10.08M	-52K	-20.41M	18.25M	-100K	-12.01M
Capital Expenditures	-40K	-64K	-76K	-207K	-4K	-52K	-2.84M	-34K	-100K	-224K
CapEx % of Revenue	-	-	-	-	-	0.29%	2.11%	0.03%	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-861K	-64K	-3.07M	3.07M	0	0	-20.41M	717K	0	-11.79M
Cash from Financing+	16.67M	14.71M	47.72M	13.24M	70.09M	117.83M	1K	3.43M	4K	26.79M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-1.2M	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	-537K	-2.78M	-755K	0	4.65M	-38K	5M	4K	22.87M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-6.61M	-13.76M	-28.87M	-40.16M	-48.17M	-43.8M	-50.09M	-28.18M	-16.57M	-16.67M
FCF Margin %	-	-	-	-	-	-243.32%	-37.07%	-20.86%	-	-
FCF Growth %	-4.77%	-1.08%	-1.1%	-0.39%	-0.2%	0.09%	-0.14%	0.44%	0.41%	-0.01%
FCF per Share	-0.42	-0.82	-1.38	-1.77	-1.95	-1.46	-1.28	-0.72	-0.43	-0.42
FCF Conversion (FCF/Net Income)	0.82x	1.14x	0.31x	0.73x	1.26x	0.72x	0.74x	0.85x	0.78x	1.48x
Interest Paid	0	0	0	0	0	85K	91K	17K	0	0
Taxes Paid	0	0	0	0	0	0	22K	367K	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-6015.09%	-109.4%	-455%	-588.28%	-350.22%	-99.18%	-113.85%	-371.5%	-	-
Return on Invested Capital (ROIC)	-	-	-10673.31%	-	-	-	-	-	-	-
Gross Margin	-	-	-	-	-	100%	100%	100%	-	-
Net Margin	-	-	-	-	-	-33873.89%	-4750.48%	-2463.29%	-	-
Debt / Equity	-	0.02x	-	-	0.13x	0.05x	0.17x	-	-	-
Interest Coverage	-14.05x	-69.88x	-	-	-195.67x	-755.42x	-761.38x	-2190.53x	-	-
FCF Conversion	0.82x	1.14x	0.31x	0.73x	1.26x	0.72x	0.74x	0.85x	0.78x	1.48x
Revenue Growth	-	-	-	-	-	-	650.56%	0%	-100%	-

Frequently Asked Questions

Growth & Financials

BeyondSpring Inc. (BYSI) grew revenue by 0.0% over the past year. Growth has been modest.

BeyondSpring Inc. (BYSI) reported a net loss of $0.6M for fiscal year 2024.

Dividend & Returns

BeyondSpring Inc. (BYSI) had negative free cash flow of $14.7M in fiscal year 2024, likely due to heavy capital investments.